Search / Trial NCT06614205

Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Sep 24, 2024

Trial Information

Current as of December 22, 2024

Not yet recruiting

Keywords

Meningioma Theragnostic Dosimetry

ClinConnect Summary

Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to cl...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patients treated for menigioma at nancy hospital
  • patients who performed 3 scintigraphics exams during there treatment
  • Exclusion Criteria:
  • patients deprived of liberty
  • patient who refused to collect data retrospectively

About Central Hospital, Nancy, France

Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0